La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Syneos Health Performance dei guadagni passati

Il passato criteri di controllo 1/6

Syneos Health ha registrato una crescita degli utili a un tasso medio annuo di 34.5%, mentre il settore Life Sciences ha registrato utili in crescita a un tasso medio annuo di 14.2%. I ricavi sono stati in crescita a un tasso medio annuo di 6.4%. Il ritorno sul capitale proprio di Syneos Health è 2% e ha margini netti di 1.3%.

Informazioni chiave

34.5%

Tasso di crescita degli utili

34.8%

Tasso di crescita dell'EPS

Life Sciences Crescita del settore	21.5%
Tasso di crescita dei ricavi	6.4%
Rendimento del capitale proprio	2.0%
Margine netto	1.3%
Ultimo aggiornamento sui guadagni	30 Jun 2023

Aggiornamenti sulle prestazioni recenti

Recent updates

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Jun 18

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Jun 03

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

May 19

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Apr 08

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Mar 27

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Mar 05

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Feb 18

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Feb 03

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Is Interesting

Jan 04

Syneos Health's Double-Digit Revenue Growth Sets The Tone For A Strong 2022

Dec 03

Is It Too Late To Consider Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Dec 03

Ripartizione dei ricavi e delle spese

Come Syneos Health guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:SYNH Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Jun 23	5,419	71	612
31 Mar 23	5,414	148	569
31 Dec 22	5,393	266	547
30 Sep 22	5,407	287	559
30 Jun 22	5,419	278	568
31 Mar 22	5,340	242	574
31 Dec 21	5,213	235	571
30 Sep 21	4,980	251	542
30 Jun 21	4,730	236	521
31 Mar 21	4,461	198	484
31 Dec 20	4,416	193	473
30 Sep 20	4,489	192	464
30 Jun 20	4,567	187	456
31 Mar 20	4,720	195	459
31 Dec 19	4,676	131	508
30 Sep 19	4,608	86	444
30 Jun 19	4,546	17	431
31 Mar 19	4,452	19	420
31 Dec 18	4,390	24	406
30 Sep 18	3,995	-36	434
30 Jun 18	3,472	-174	426
31 Mar 18	2,658	-184	368
31 Dec 17	1,853	-138	314
30 Sep 17	1,365	-86	221
30 Jun 17	1,033	89	174
31 Mar 17	1,033	116	174
31 Dec 16	1,030	113	172
30 Sep 16	1,009	106	171
30 Jun 16	984	116	170
31 Mar 16	952	109	164
31 Dec 15	915	117	157
30 Sep 15	887	33	154
30 Jun 15	860	8	152
31 Mar 15	837	0	149
31 Dec 14	810	-27	145
30 Sep 14	770	13	139
30 Jun 14	732	-1	128
31 Mar 14	687	-27	123
31 Dec 13	652	-42	118
31 Dec 12	579	-60	109

Guadagni di qualità: SYNH ha un grande una tantum perdita di $132.0M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2023.

Margine di profitto in crescita: Gli attuali margini di profitto netti di SYNH (1.3%) sono inferiori rispetto allo scorso anno (5.1%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: SYNH è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 34.5% all'anno.

Accelerare la crescita: SYNH ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: SYNH ha avuto una crescita negativa degli utili ( -74.4% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Life Sciences ( -10.8% ).

Syneos Health Performance dei guadagni passati

Il passato criteri di controllo 1/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Syneos Health Files Form 15

Syneos Health, Inc. Announces Chief Executive Officer Changes

Syneos Health, Inc. Announces Management Changes

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C completed the acquisition of Syneos Health, Inc. (NasdaqGS:SYNH) from a group of shareholders.

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Levi & Korsinsky Notifies Syneos Health, Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Consensus EPS estimates fall by 70%

The Klein Law Firm Announces That a Class Action Complaint Has Been Filed on Behalf of Shareholders of Syneos Health, Inc

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Syneos Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Syneos Health, Inc

Syneos Health Appoints Hillary Bochniak as Chief Human Resources Officer

Syneos Health, Inc. Appoints Batisha Anson to Global Head, Patient Diversity and Health Equity

Consensus EPS estimates fall from profit to US$0.31 loss, revenue upgraded

Patient Square Capital, LP, Elliott Investment Management L.P. and Veritas Capital Fund Management, L.L.C entered into an agreement to acquire Syneos Health, Inc. (NasdaqGS:SYNH) in a transaction valued at approximately $7.5 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

Does Syneos Health (NASDAQ:SYNH) Have A Healthy Balance Sheet?

Is Syneos Health, Inc. (NASDAQ:SYNH) Trading At A 40% Discount?

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Syneos Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 11%

Price target decreased by 10% to US$36.95

Syneos Health, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Syneos Health, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Should You Investigate Syneos Health, Inc. (NASDAQ:SYNH) At US$34.33?

Is Syneos Health (NASDAQ:SYNH) Using Too Much Debt?

High number of new directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

Here's Why Syneos Health (NASDAQ:SYNH) Has Caught The Eye Of Investors

Syneos Health Adds Hub Patient Suite to Deployment Solutions Business

Syneos Health, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Syneos Health, Inc. Announces Executive Changes

Price target decreased to US$69.73

Syneos, Datavant expand partnership on data analytics for clinical trials

Investor sentiment deteriorated over the past week

Syneos Health falls 13% after update on outlook

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Syneos Health, Inc. (NasdaqGS:SYNH) acquired Boco Digital Media, LLC.

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syneos Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Syneos Health Q2 2022 Earnings Preview

With EPS Growth And More, Syneos Health (NASDAQ:SYNH) Makes An Interesting Case

Syneos Health, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Syneos: Upside Could Be Priced In, Valuations Unsupportive

Is There An Opportunity With Syneos Health, Inc.'s (NASDAQ:SYNH) 49% Undervaluation?

Is Now The Time To Look At Buying Syneos Health, Inc. (NASDAQ:SYNH)?

We Think Syneos Health (NASDAQ:SYNH) Can Stay On Top Of Its Debt

Consensus forecasts updated

High number of new directors

Syneos Health, Inc. Revises Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

Syneos Health Announces Executive Promotions

Syneos Health, Inc., Annual General Meeting, May 25, 2022

Syneos Health, Inc. to Report Q1, 2022 Results on Apr 29, 2022

Do Syneos Health's (NASDAQ:SYNH) Earnings Warrant Your Attention?

Syneos Health: Upside Opportunity After Unexpected Correction In CRO Market, M&A Rumors

Is Now An Opportune Moment To Examine Syneos Health, Inc. (NASDAQ:SYNH)?

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Syneos Health, Inc. Provides Earnings Guidance for the First Quarter of 2022

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Are Investors Undervaluing Syneos Health, Inc. (NASDAQ:SYNH) By 39%?

Syneos Health, Inc. to Report Q4, 2021 Results on Feb 17, 2022